Article

Efficient Delivery Of AAV Therapies To Patients Via Candidate Screening And Feasibility Studies

GettyImages-1185230425-indoc-AAV-petri-dish

As drug developers embark on the early leg of their adeno-associated virus (AAV) therapy research and development journeys, drug candidate screening and feasibility studies help achieve preclinical and Phase 1 goals while minimizing cost and time spent. Early-phase assessment studies aim to create simple, modular paths to current good manufacturing practice (cGMP) to minimize risk and streamline drug substance and drug product manufacturing. When assessing potential manufacturing partners, consider a contract development and manufacturing organization (CDMO) that offers candidate screening and feasibility studies to optimize your process and expedite your path to cGMP.

To manufacture your AAV gene therapy with high quality and efficiency, work with an experienced AAV manufacturer that prioritizes innovative and effective technologies to meet clinical challenges while employing experienced teams that understand how to advance your product from preclinical development to commercialization. Download the full whitepaper to learn more about how consistent and predictive modules can be used to deliver next-generation therapeutics seamlessly.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

FUJIFILM Diosynth Biotechnologies